Clinical Trial: Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235930) titled 'Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer' on Nov. 13.

Brief Summary: A randomized, multicenter, Phase III trial evaluating the efficacy and safety of first-line Sequential AG-mFOLFOX chemotherapy combined with Serplulimab and Bevacizumab versus AG chemotherapy alone in advanced pancreatic cancer. The primary endpoint is Overall Survival (OS). Approximately 292 patients will be enrolled in China.

Study Start Date: Nov. 15

Study Type: INTERVENTIONAL

Condition: Non-Resectable Pancreas Carcinoma

Intervention: DRUG: Sequential AG and mFO...